India accounts for approximately one-fifth of all global cardiovascular disease (CVD)-related deaths. A 2024 systematic review and meta-analysis places the pooled prevalence of CVD among Indian adults at 11%, with urban populations bearing a higher burden at 12% compared to 6% in rural settings. Coronary artery disease (CAD) prevalence in India's urban population has risen from 1-2% in the 1960s to approximately 10-12% in recent years.
CVDs strike Indians a decade
earlier than their western counterparts. Hospital admission rates for CAD
complications are reportedly 5-10 times higher among those under 40 years of
age. In 2016, cardiovascular diseases contributed to 28.1% of all deaths in
India, a figure that more than doubled since 1990.
Within this context, managing heart
blockages remains a pressing clinical challenge. While bypass surgery and
angioplasty dominate conventional treatment, a scientifically validated,
non-invasive modality has long existed: Enhanced External Counterpulsation(EECP). Despite FDA approval and cardiology guideline recognition, EECP remains
widely underutilised.
Understanding Coronary Artery Disease
Heart blockage refers to the
progressive atherosclerotic narrowing of coronary arteries, the vessels
responsible for supplying oxygenated blood to the myocardium. When fatty
deposits, cellular debris, and calcium accumulate within arterial walls, they
form plaques that restrict luminal diameter and reduce myocardial perfusion.
CAD spans a spectrum of severity.
Blockages below 40% are generally asymptomatic, though they signal an
established atherosclerotic process. Moderate blockages (40-70%) may cause
exertional symptoms. Severe obstructions above 75% significantly compromise
cardiac output and are frequently linked to stable angina, heart failure, or
acute coronary syndromes.
A critical and often overlooked
factor is endothelial dysfunction. The arterial disease is not merely
cholesterol accumulation; it is fundamentally a disease of the vascular
endothelium. Endothelial dysfunction precedes visible plaque formation and
drives the inflammatory cascade underlying atherosclerosis. The heart's
compensatory mechanism, collateral circulation, also plays a decisive role.
When a coronary artery becomes progressively obstructed, the myocardium
attempts to maintain perfusion through collateral vessels that reroute blood
around blocked segments.
Risk Factors and the Indian Patient Profile
The INTERHEART study established
that over 90% of the risk for a first myocardial infarction is attributable to
measurable, modifiable risk factors. In the Indian population, the convergence
of metabolic, lifestyle, and genetic susceptibilities creates a particularly
vulnerable profile:
● Hypertension is prevalent in approximately 30%
of the Indian adult population and remains a foremost driver of accelerated
atherosclerosis.
● Diabetes mellitus is present in 10-12% of
Indians. The prevalence of CAD in diabetic Indians is reported at 21.4%,
compared to 11% in non-diabetics.
● Dyslipidaemia contributes a population
attributable risk of 39% for cardiovascular events globally.
● Less than 10% of the studied Indian population
engages in regular physical activity, making sedentary behaviour a significant
and modifiable risk factor.
● Indians are genetically predisposed to CAD,
with migrant Asian Indians showing up to three times higher prevalence than
many other ethnic groups.
● Early-onset disease is a defining feature;
Indians develop CAD a full decade earlier than Western populations.
Conventional Treatment: Efficacy and Gaps
Standard CAD management spans
pharmacotherapy, interventional procedures, and surgical revascularisation.
Each serves a defined role, yet none is without significant limitation.
Pharmacotherapy
Antiplatelet agents, statins,
beta-blockers, and nitrates form the pharmacological backbone of CAD
management. They reduce event risk and slow disease progression but do not
restore occluded vessels or develop new perfusion pathways. The PURE study
found that up to three-fourths of CAD patients in India are not receiving even
basic guideline-recommended therapy.
Angioplasty and Bypass Surgery
PCI with stent placement is
effective for focal lesions and acute syndromes but addresses only a single
obstruction, leaving the broader vascular disease untreated. Coronary Artery
Bypass Grafting (CABG) offers durable revascularisation for multi-vessel disease,
but carries the full morbidity of open-heart surgery. A significant proportion
of patients with refractory angina are ineligible for repeat intervention due
to anatomical complexity or comorbidities.
This therapeutic gap, patients who
remain symptomatic despite optimal therapy or who are unsuitable for invasive
intervention, is precisely the clinical space EECP was developed to address.
EECP: The Science of Natural Bypass
Enhanced External Counterpulsation
(EECP) is an FDA-approved, CE-marked, non-invasive outpatient therapy for
chronic stable angina and heart failure. Pneumatic cuffs wrapped around the
calves, lower thighs, and buttocks are synchronised with the patient's cardiac
cycle via ECG monitoring. During diastole, sequential inflation of the cuffs
generates augmented aortic pressure, increasing coronary perfusion. Rapid
deflation at the onset of systole reduces cardiac afterload and workload. This
counterpulsation mechanism delivers haemodynamic benefits comparable to an
intra-aortic balloon pump, without any invasive access.
Peer-reviewed literature documents
the following cumulative benefits of a standard 35-session EECP course:
● Collateral vessel development: EECP promotes
angiogenesis and recruitment of dormant collateral channels, creating natural
biological bypasses around obstructed coronary segments.
● Endothelial restoration: The therapy induces
shear stress across vascular endothelium, stimulating nitric oxide release and
suppressing endothelin. Elevated nitric oxide levels have been confirmed to
persist for at least one month post-treatment.
● Neurohormonal modulation: EECP inhibits the
Renin-Angiotensin-Aldosterone System (RAAS), reduces plasma BNP levels, and
decreases cardiac pre-load and afterload.
● Clinical outcomes: Published data confirm a
15.5% increase in mean exercise time and a 27% improvement in peak oxygen
uptake at six-month follow-up. In a multicentre registry of 466 patients, the
therapy demonstrated significant and sustained reduction in angina frequency.
Unlike stenting, which addresses a
single arterial lesion, EECP improves the entire coronary and systemic vascular
network. Clinical trials confirm that EECP reduces repeat hospitalisation,
improves functional status, and enhances quality of life across both ischaemic
and idiopathic cardiomyopathy. The therapy has no significant side effects and
carries no surgical risk, making it accessible to elderly patients and those
with advanced comorbidities who are typically excluded from invasive options.
Appropriate Candidates for EECP
EECP is clinically indicated for:
● Patients with chronic stable angina who remain
symptomatic despite optimal pharmacotherapy.
● Individuals with diffuse multi-vessel CAD
unsuitable for angioplasty or bypass surgery.
● Post-CABG or post-PCI patients with recurrent
symptoms where further revascularisation carries prohibitive risk.
● Heart failure patients (NYHA Class II-III)
seeking improved functional capacity.
● Patients who decline surgical intervention or
have medical contraindications to invasive procedures.
The standard protocol consists of
35 one-hour outpatient sessions over 7 weeks, conducted six days per week. No
hospitalisation, anaesthesia, or recovery period is required, and patients
continue prescribed medications throughout.
Heal Your Heart: Advancing Non-Invasive
Cardiac Care
Heal Your Heart, operating under
Vaso-Meditech Private Limited, has pioneered EECP delivery across India since
2001. With over 27 centres in 10 cities and a capacity exceeding 70,000
sessions annually, it represents the largest EECP programme in the world. Their
clinical approach integrates thorough cardiac assessment, second-opinion
consultation for patients facing invasive recommendations, and a commitment to
patient-centred care.
For patients navigating the
complexity of coronary artery disease, particularly those for whom surgical
revascularisation is inadvisable or undesired, Heal Your Heart provides access
to evidence-based, non-invasive cardiac restoration.
Conclusion
The management of heart blockages
has historically been framed around medication or surgery. This framing
inadequately reflects both the biological complexity of coronary artery disease
and the available evidence for non-invasive therapeutics.
EECP therapy does not merely mask
symptoms. It addresses the underlying haemodynamic and vascular dysfunction
that defines CAD by augmenting coronary perfusion pressure, stimulating
angiogenesis, restoring endothelial function, and modulating neurohormonal
pathways. These systemic benefits cannot be replicated by a procedure confined
to a single arterial lesion.
For the millions of Indian patients
living with coronary artery disease, burdened by angina, limited exercise
capacity, and justified concern about surgical risk, EECP offers a clinically
credible and durable path toward improved cardiac function and quality of life.
The hidden power of EECP lies not
in its novelty, but in its under-appreciation. That is a therapeutic reality
the cardiac community, patients, and healthcare decision-makers must work
together to change.
For More info : www.healurheart.com
Comments
Post a Comment